Ex-Vivo Skin Explant Culture Is a Model for TSLP-Mediated Skin Barrier Immunity

The skin is the outermost barrier protecting the body from pathogenic invasion and environmental insults. Its breakdown initiates the start of skin inflammation. The epidermal growth factor (EGFR) on keratinocytes protects this barrier, and its dysfunction leads to atopic dermatitis-like skin disease. One of the initial cytokines expressed upon skin barrier breach and during atopic dermatitis is TSLP. Here, we describe the expression and secretion of TSLP during EGFR inhibition and present an ex-vivo model, which mimics the early events after barrier insult. Skin explants floated on culture medium at 32 °C released TSLP in parallel to the activation of the resident Langerhans cell network. We could further show the up-regulation and activation of the AP-1 family of transcription factors during atopic-like skin inflammation and its involvement in TSLP production from the skin explant cultures. Inhibition of the c-Jun N-terminal kinase pathway led to a dose-dependent blunting of TSLP release. These data indicate the involvement of AP-1 during the early stages of atopic-like skin inflammation and highlight a novel therapeutic approach by targeting it. Therefore, skin explant cultures mimic the early events during skin barrier immunity and provide a suitable model to test therapeutic intervention.

[1]  E. Wagner,et al.  Psoriatic skin inflammation is promoted by c‐Jun/AP‐1‐dependent CCL2 and IL‐23 expression in dendritic cells , 2021, EMBO molecular medicine.

[2]  S. Eberlin,et al.  The Ex Vivo Skin Model as an Alternative Tool for the Efficacy and Safety Evaluation of Topical Products , 2020, Alternatives to laboratory animals : ATLA.

[3]  T. Mohr,et al.  Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy , 2019, Science Translational Medicine.

[4]  S. Ziegler,et al.  TSLP: from allergy to cancer , 2019, Nature Immunology.

[5]  T. Bieber,et al.  Atopic dermatitis , 2018, Nature Reviews Disease Primers.

[6]  M. Fischbach,et al.  Skin microbiota–host interactions , 2018, Nature.

[7]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[8]  M. Hung,et al.  JNK1 negatively controls anti-fungal innate immunity by suppressing CD23 expression , 2017, Nature Medicine.

[9]  M. Baccarini,et al.  Epidermal RAF prevents allergic skin disease , 2016, eLife.

[10]  M. Holcmann,et al.  Mechanisms underlying skin disorders induced by EGFR inhibitors , 2015, Molecular & cellular oncology.

[11]  G. Lemke.  Biology of the TAM receptors. , 2013, Cold Spring Harbor perspectives in biology.

[12]  M. Pellegrino,et al.  The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch , 2013, Cell.

[13]  J. Fischer,et al.  Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation , 2013, Science Translational Medicine.

[14]  C. Berking,et al.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.

[15]  G. Lemke,et al.  Identification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasis , 2012, The Journal of experimental medicine.

[16]  S. Molyneux,et al.  Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. , 2012, Immunity.

[17]  Yong‐jun Liu,et al.  Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. , 2007, The Journal of allergy and clinical immunology.

[18]  E. Wagner,et al.  Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins , 2005, Nature.

[19]  S. Ziegler,et al.  Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin , 2005, The Journal of experimental medicine.

[20]  G. Schuler,et al.  Matrix Metalloproteinases 9 and 2 Are Necessary for the Migration of Langerhans Cells and Dermal Dendritic Cells from Human and Murine Skin1 , 2002, The Journal of Immunology.

[21]  A. Giannetti,et al.  Dysregulated activation of activator protein 1 in keratinocytes of atopic dermatitis patients with enhanced expression of granulocyte/macrophage-colony stimulating factor. , 2000, The Journal of investigative dermatology.

[22]  B. Ryffel,et al.  Migration of Langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by TNF‐α and IL‐1 β , 1999, Journal of leukocyte biology.

[23]  J. Smolle,et al.  Entry into afferent lymphatics and maturation in situ of migrating murine cutaneous dendritic cells. , 1998, The Journal of investigative dermatology.